Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10415650 | 0.98 | DRD2 (0.49) | DRD2PRMT5WDR77TP53ACHE | |
| Hydrochloric Acid SCHEMBL1625872 | 0.98 | DRD2 (0.49) | DRD2PRMT5WDR77TP53ACHE | |
| SCHEMBL5646802 | 0.89 | GBA1 (0.47) | PRMT5WDR77 | |
| SCHEMBL38653916 | 0.89 | DRD2 (0.59) | DRD2PRMT5WDR77TP53ACHE | |
| Hydrochloric Acid SCHEMBL9633666 | 0.87 | GBA1 (0.46) | — | |
| SCHEMBL38653251 | 0.85 | PRMT5 (0.54) | DRD2PRMT5WDR77TP53 | |
| SCHEMBL5687764 | 0.85 | ACHE (0.65) | DRD2ACHE | |
| SCHEMBL2437081 | 0.84 | PRMT5 (0.56) | DRD2PRMT5WDR77 | |
| SCHEMBL2616312 | 0.83 | MAOA (0.55) | DRD2TP53ACHETHRBLMNA | |
| Hydrochloric Acid SCHEMBL14974971 | 0.83 | PRMT5 (0.55) | DRD2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2025481-A | — | — | None | — | — | JP | disclosed |
| JP-1100167-A | — | — | None | — | — | JP | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-1831195-B1 | 5-HT7 RECEPTOR ANTAGONISTS | ESTEVE LABOR DR (ES) | 2012-12-19 | — | — | EP | disclosed |
| US-7928121-B2 | 2-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolinehydrochloride; antidepressant, anxiolytic, hypotensive agent; psychosis, schizophrenia, migraine, cognition activity; pharmacokinetics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-19 | — | — | US | disclosed |
| US-7928121-B2 | 2-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolinehydrochloride; antidepressant, anxiolytic, hypotensive agent; psychosis, schizophrenia, migraine, cognition activity; pharmacokinetics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-04-19 | — | — | US | disclosed |
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DE DR. ESTEVE, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
| US-7345057-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-18 | — | — | US | disclosed |
| US-4945096-A | Treatment of a depressive state with 2-[(4-piperidyl)methyl]-1,2,3,4-tetrahydroisoquinoline derivates | SYNTHELABO (FR) | 1990-07-31 | — | — | US | disclosed |
| US-4940645-A | Imaging material employing photosensitive microcapsules containing tertiary amines as coinitiators | THE MEAD CORPORATION (US) | 1990-07-10 | — | — | US | disclosed |
| US-4925850-A | SLEEP, CARDIOVASCULAR, AND NERVOUS SYSTEM DISORDERS; DIETETICS, ANXIOLYTIC AGENTS | SYNTHELABO (FR) | 1990-05-15 | — | — | US | disclosed |
| US-4925850-A | SLEEP, CARDIOVASCULAR, AND NERVOUS SYSTEM DISORDERS; DIETETICS, ANXIOLYTIC AGENTS | SYNTHELABO (FR) | 1990-05-15 | — | — | US | disclosed |
| JP-H0225481-A | 2-((4-PIPERIDINYL)METHYL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVE, ITS PRODUCTION AND ITS APPLICATION IN IHERAPEUTICS | SYNTHELABO SA | 1990-01-26 | — | — | JP | disclosed |
| EP-0351255-A2 | Derivatives of 2-[(4-piperidinyl)methyl]-1,2,3,4-tetrahydroisoquinoline, their preparation and their use in therapy | SYNTHELABO (FR) | 1990-01-17 | — | — | EP | disclosed |
| US-4885302-A | 2-((4-Piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their application in therapy | SYNTHELABO, 58, RUE DE LA GLACIERE - 75013 PARIS | 1989-12-05 | — | — | US | disclosed |
| US-4885302-A | 2-((4-Piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their application in therapy | SYNTHELABO, 58, RUE DE LA GLACIERE - 75013 PARIS | 1989-12-05 | — | — | US | disclosed |
| JP-H01100167-A | 2-((4-PIPERIDYL)METHYL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVE | SYNTHELABO SA | 1989-04-18 | — | — | JP | disclosed |
| EP-0306375-A1 | 2-[(4-Piperidinyl)methyl]-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214603-A1 | 5-Ht7 Receptor Antagonists | HTR7, HTR1A, HTR5A | DRD2 39/4885PRMT5 1967/4885WDR77 3403/4885 |
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PAH, HMBS, P4HA1 | DRD2 1033/4885PRMT5 109/4885WDR77 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.